Member Login

              Click here if you forgot your password.

Current Events

Qualified Person Education Course Module A - Live Online Training

29/30 November 2023
Live Online

EQPA Members Area

IMP Working Group Members Area

Document and track your personal development - with the Continuous Professional Development (CPD) Documentation Template

To access the template for documenting and tracking your past and ongoing activities, please go here.

After filling out the form, you will be able to create and print out a PDF file.

Brexit: Two new Documents published by EMA


The European Medicines Agency (EMA) published two updated documents on the United Kingdom's (U.K.) withdrawal from the European Union (EU, the so called Brexit:

1. Questions and Answers Document (Rev 03, published on 19 June 2018)
2. Practical guidance for procedures related to Brexit (Rev 02 2, EMA/478309/2017, published on 19 June 2018)

This list of Q&As has initially been drafted jointly by the Directorate-General for Health and Food Safety of the European Commission and EMA. This reversion now amends the initial list of Q&As published on 31 May 2017 replacing all previous versions of Q&As. The new text introduced in this document is indicated by the word "NEW". So what is "NEW"? EMA has added seven new Q&As and amended earlier answers:

Questions (and answers) have been added with respect to:

  • Official Control Authority Batch Release (OCABR) processes (currently tested by a UK Official Medicines Control Laboratory)
  • Influence on the status of inspection outcomes by the UK competent authority?
  • Influence on the CE certification of medical devices
  • Impact o the CHMP scientific opinion for ancillary medicinal substances in medical devices
  • Impact on the possibility to market multi-country packs
  • Back-up arrangements in the UK for Qualified Persons for Pharmacovigilance (QPPV)

The Practical Guidance document complements the Q&As to provide procedural and practical guidance regarding submission of changes and related fees. New questions and headings amend the following topics:

  • Variations
  • Transfer of orphan designation
  • QPPV and the pharmacovigilance system
  • Ongoing initial marketing authorisation procedures
  • CHMP scientific opinion under Article 58
  • Paediatric investigation plans and waivers
  • Contact point at the EMA
  • Impact on Rapporteurships
  • Product Information
  • Official Control Authority Batch Release
  • National scientific advice issued by UK authorities


Conference Recommendations